Research and Markets: Stakeholder Opinions: Sexual Dysfunction - The Quest for the New Viagra Continues

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/51abf9/stakeholder_opinio) has announced the addition of the "Stakeholder Opinions: Sexual Dysfunction - The Quest for the New Viagra Continues" report to their offering.

Drug developers interested on the sexual dysfunction market are searching for the next Viagra. Companies are focusing on premature ejaculation and female hypoactive sexual desire disorder, which are suggested to be as prevalent as erectile dysfunction. As products advance through the pipeline, there are several challenges that will have to be addressed in order to succeed in these markets.

Scope

  • Overview of erectile dysfunction, premature ejaculation and female sexual dysfunction disorders including epidemiology and key unmet needs.
  • Summary of the drug classes currently used for the different sexual dysfunction disorders and an update of the latest proposed treatment guidelines.
  • Evaluation of marketed brands and pipeline agents for erectile dysfunction, premature ejaculation and female sexual dysfunction disorders.
  • Insights from interviews with seven leading US and European key opinion leaders in the field of male and female sexual dysfunction.

Highlights of this title

  • The erectile dysfunction market will remain the most attractive and accepted one among the different sexual dysfunction disorders for the foreseeable future, although Johnson & Johnson is well positioned to develop the premature ejaculation area with the launch of Priligy (dapoxetine) in the EU.
  • Companies entering the sexual dysfunction market will have to follow the example of Viagra (sildenafil, Pfizer) and invest heavily in direct to consumer marketing in the US. A strong marketing message will be vital to raising awareness and beginning the campaign to destigmatize the different disorders.
  • There is high R&D risk in the associated with the development of drugs for female sexual dysfunction due to the lack of clear disorder definition and trial endpoints, the strong placebo effect of drugs and the scrutiny of regulatory bodies. As such Boehringer Ingelheim's flibanserin and BioSante's LibiGel (testosterone) approval is not guaranteed.

Key reasons to purchase this title

  • Understand the prevalence of erectile dysfunction, premature ejaculation and female sexual dysfunction.
  • Identify the key clinical unmet needs in the treatment of male and female sexual dysfunction as determined by interviewed key opinion leaders.
  • Evaluate the potential of key strategies companies can employ to increase their presence in the sexual dysfunction disorder markets.

Key Topics Covered:

1. Sexual Dysfunction - Patient Potential

2. Sexual Dysfunction - Market Potential

3. Brand Dynamics

4. Pipeline Analysis

5. Case Studies

For more information visit http://www.researchandmarkets.com/research/51abf9/stakeholder_opinio

Source: Datamonitor



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.